The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3527-3538

  Gojo, Ivana ^a   Zhang, Bin ^a   Fenton, Robert G ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RNA POLYMERASE II; BCL2L1 PROTEIN, HUMAN; CASPASE; CYCLIN DEPENDENT KINASE; FLAVONOID; MCL1 PROTEIN; MEMBRANE PROTEIN; PIPERIDINE DERIVATIVE; PROTEIN BCL X; PROTEOGLYCAN; SYNDECAN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS; TRANSCRIPTION REGULATION; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG RESISTANCE; GENETIC TRANSCRIPTION; METABOLISM; NICK END LABELING; NORTHERN BLOTTING; PATHOLOGY; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; TIME; WESTERN BLOTTING;

APOPTOSIS; BCL-X PROTEIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CASPASES; CELL DIVISION; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; IN SITU NICK-END LABELING; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PHOSPHORYLATION; PIPERIDINES; PROTEIN STRUCTURE, TERTIARY; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SYNDECANS; TIME FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0036850211     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Rajkumar, S. V., and Greipp, P. R. Prognostic factors in multiple myeloma. Hematol. Oncol. Clin. N. Am., 13: 1295-1314, xi, 1999.
2. Hallek, M., Bergsagel, P. L., and Anderson, K. C. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood, 91: 3-21, 1998.
3. Fernberg, J. O., Johansson, B., Lewensohn, R., and Mellstedt, H. Oral dosage of melphalan and response to treatment in multiple myeloma. Eur. J. Cancer, 26: 393-396, 1990.
4. Gregory, W. M., Richards, M. A., and Malpas, J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J. Clin. Oncol., 10: 334-342, 1992.
5. Alexanian, R., Barlogie, B., and Dixon, D. High-dose glucocorticoid treatment of resistant myeloma. Ann. Intern. Med., 105: 8-11, 1986.
6. Alexanian, R., Barlogie, B., and Tucker, S. VAD-based regimens as primary treatment for multiple myeloma. Am. J. Hematol., 33: 86-89, 1990.
7. Alexanian, R., Dimopoulos, M. A., Delasalle, K., and Barlogie, B. Primary dexamethasone treatment of multiple myeloma. Blood, 80: 887-890, 1992.
8. Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G., Rossi, J. F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., and Bataille, R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med., 335: 91-97, 1996.
9. Jagannath, S., Tricot, G., and Barlogie, B. Autotransplants in multiple myeloma: Pushing the envelope. Hematol. Oncol. Clin. N. Am., 11: 363-381, 1997.
10. Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., and Tricot, G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89: 789-793, 1997.
11. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., and Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93: 1658-1667, 1999.
12. Carter, A., Merchav, S., Silvian-Draxler, I., and Tatarsky, I. The role of interleukin-1 and tumour necrosis factor-α in human multiple myeloma. Br. J. Haematol., 74: 424-431, 1990.
13. Cozzolino, F., Torcia, M., Aldinucci, D., Rubartelli, A., Miliani, A., Shaw, A. R., Lansdorp, P. M., and Di Guglielmo, R. Production of interleukin-1 by bone marrow myeloma cells. Blood, 74: 380-387, 1989.
14. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T. A., and Anderson, K. C. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κ B. Blood, 87: 1104-1112, 1996.
15. Witzig, T. E. The role of adhesion receptors in the pathogenesis of multiple myeloma. Hematol. Oncol. Clin. N. Am., 13: 1127-1143, 1999.
16. Klein, B., Zhang, X. G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., and Bataille, R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73: 517-526, 1989.
17. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., and et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (Lond.), 332: 83-85, 1988.
18. Zhang, X. G., Bataille, R., Widjenes, J., and Klein, B. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer (Phila.), 69: 1373-1376, 1992.
19. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., and Berenson, J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol., 162: 248-255, 1995.
20. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. Interleukin-6-type cytokine signalling through the gp130/ Jak/STAT pathway. Biochem. J., 334: 297-314, 1998.
21. Jelinek, D. F. Mechanisms of myeloma cell growth control. Hematol. Oncol. Clin. N. Am., 13: 1145-1157, 1999.
22. Ogata, A., Chauhan, D., Teoh, G., Treon, S. P., Urashima, M., Schlossman, R. L., and Anderson, K. C. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol., 159: 2212-2221, 1997.
23. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., and Jove, R, Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10: 105-115, 1999.
24. Puthier, D., Bataille, R., and Amiot, M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur. J. Immunol., 29: 3945-3950, 1999.
25. Ong, F., van Nieuwkoop, J. A., de Groot-Swings, G. M., Hermans, J., Harvey, M. S., Kluin, P. M., and Kluin-Nelemans, J. C. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia (Baltimore), 9: 1282-1284, 1995.
26. Puthier, D., Pellat-Deceunynck, C., Barille, S., Robillard, N., Rapp, M. J., Juge-Morineau, N., Harousseau, J. L., Bataille, R., and Amiot, M. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia (Baltimore), 13: 289-294, 1999.
27. Miguel-Garcia, A., Orero, T., Matutes, E., Carbonell, F., Miguel-Sosa, A., Linares, M., Tarin, F., Herrera, M., Garcia-Talavera, J., and Carbonell-Ramon, F. Bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica, 83: 298-304, 1998.
28. Tu, Y., Renner, S., Xu, F., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J. C., and Lichtenstein, A. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res., 58: 256-262, 1998.
29. Gauthier, E. R., Piche, L., Lemieux, G., and Lemieux, R. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. Cancer Res., 56: 1451-1456, 1996.
30. Puthier, D., Derenne, S., Barille, S., Moreau, P., Harousseau, J. L., Bataille, R., and Amiot, M. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br. J. Haematol., 107: 392-395, 1999.
31. Akgul, C., Turner, P. C., White, M. R., and Edwards, S. W. Functional analysis of the human MCL-1 gene. Cell Mol Life Sci., 57: 684-691, 2000.
32. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., and Craig, R. W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. USA, 90: 3516-3520, 1993.
33. Rechsteiner, M., and Rogers, S. W. PEST sequences and regulation by proteolysis. Trends Biochem. Sci., 21: 267-271, 1996.
34. Zhang, B., Gojo, I., and Fenton, R. G. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood, 99: 1885-1893, 2002.
35. Kitada, S., Zapata, J. M., Andreeff, M., and Reed, J. C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 96: 393-397, 2000.
36. Kitada, S., Andersen, J., Akar, S., Zapata, J. M., Takayama, S., Krajewski, S., Wang, H. G., Zhang, X., Bullrich, F., Croce, C. M., Rai, K., Hines, J., and Reed, J. C. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood, 91: 3379-3389, 1998.
37. Moulding, D. A., Quayle, J. A., Hart, C. A., and Edwards, S. W. Mcl-1 expression in human neutrophils: Regulation by cytokines and correlation with cell survival. Blood, 92: 2495-502, 1998.
38. Moulding, D. A., Giles, R. V., Spiller, D. G., White, M. R., Tidd, D. M., and Edwards, S. W. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood, 96: 1756-1763, 2000.
39. Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., and Reed, J. C. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood, 91: 991-1000, 1998.
40. Sedlacek, H. H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol.-Hematol., 38: 139-170, 2001.
41. Senderowicz, A. M. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. Investig. New Drugs, 17: 313-320, 1999.
42. Senderowicz, A. M., and Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst., 92: 376-387, 2000.
43. Worland, P. J., Kaur, G., Stetler-Stevenson, M., Sebers, S., Sartor, O., and Sausville, E. A. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased HI kinase activity. Biochem. Pharmacol., 46: 1831-1840, 1993.
44. De Azevedo, W. F., Jr., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93: 2735-2740, 1996.
45. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sausville, E. A., and Senderowicz, A. M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 59: 4634-4641, 1999.
46. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. 8: S32-S37, 2002.
47. Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A., Monks, A. P., Hollingshead, M. G., Sausville, E. A., and Staudt, L. M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol., 2: 1-11, 2001.
48. Harper, J. W., and Elledge, S. J. The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev., 12: 285-289, 1998.
49. Hampsey, M. Molecular genetics of the RNA polymerase 11 general transcriptional machinery. Microbiol. Mol. Biol. Rev., 62: 465-503, 1998.
50. Price, D. H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol., 20: 2629-2634, 2000.
51. Chao, S. H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., and Price, D. H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem., 275: 28345-8, 2000.
52. Chao, S. H., and Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem., 276: 31793-31793-31799, 2001.
53. Senderowicz, A. M. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia (Baltimore), 15: 1-9, 2001.
54. Decker, R. H., Dai, Y., and Grant, S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ., 8: 715-724, 2001.
55. Cartee, L., Wang, Z., Decker, R. H., Chellappan, S. P., Fusaro, G., Hirsch, K. G., Sankala, H. M., Dent, P., and Grant, S. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res., 61: 2583-2591, 2001.
56. Pepper, C., Thomas, A., Hoy, T., Fegan, C., and Bentley, P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br. J. Haematol., 114: 70-77, 2001.
57. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M. D., Pommier, Y., Sausville, E. A., and Senderowicz, A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91: 458-465, 1998.
58. Feinman, R., Koury, J., Thames, M., Barlogie, B., Epstein, J., and Siegel, D. S. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood, 93: 3044-3052, 1999.
59. Reed, J. C. Bcl-2 family proteins. Oncogene, 17: 3225-3236, 1998.
60. Gross, A., McDonnell, J. M., and Korsmeyer, S. J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev., 13: 1899-911, 1999.
61. Diehl, J. A., Zindy, F., and Sherr, C. J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev., 11: 957-972, 1997.
62. Dahmus, M. E. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J. Biol. Chem., 271: 19009-19012, 1996.
63. Casse, C., Giannoni, F., Nguyen, V. T., Dubois, M. F., and Bensaude, O. The transcriptional inhibitors, actinomycin D and α-amanitin, activate the HIV-1 promoter and favor phosphorylation of the RNA polymerase II C-terminal domain. J. Biol. Chem., 274: 16097-16106, 1999.
64. Yankulov, K., Yamashita, K., Roy, R., Egly, J. M., and Bentley, D. L. The transcriptional elongation inhibitor 5, 6-dichloro-1-β-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. J. Biol. Chem., 270: 23922-23925, 1995.
65. Zandomeni, R., Mittleman, B., Bunick, D., Ackerman, S., and Weinmann, R. Mechanism of action of dichloro-β-D-ribofuranosylbenzimidazole: Effect on in vitro transcription. Proc. Natl. Acad. Sci. USA, 79: 3167-3170, 1982.
66. Robey, R. W., Medina-Perez, W. Y., Nishiyama, K., Lahusen, T., Miyake, K., Litman, T., Senderowicz, A. M., Ross, D. D., and Bates. S. E. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res., 7: 145-152, 2001.
67. Hooijberg, J. H., Broxterman, H. J., Heijn, M., Fles, D. L., Lankelma, J., and Pinedo, H. M. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett., 413: 344-348, 1997.
68. Hooijberg, J. H., Broxterman, H. J., Scheffer, G. L., Vrasdonk, C., Heijn, M., de Jong, M. C., Scheper, R. J., Lankelma, J., and Pinedo, H. M. Potent interaction of flavopiridol with MRP1. Br. J. Cancer, 81: 269-276, 1999.
69. Semenov, I., Akyuz, C., Roginskaya, V., Chauhan, D., and Corey, S. J. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk. Res., 26: 271-280, 2002.
70. Chao, J. R., Wang, J. M., Lee, S. F., Peng, H. W., Lin, Y. H., Chou, C. H., Li, J. C., Huang, H. M., Chou, C. K., Kuo, M. L., Yen, J. J., and Yang-Yen, H. F. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol. Cell. Biol., 18: 4883-4898, 1998.
71. Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., and Grever, M. R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood, 92: 3804-3816, 1998.
72. Konig, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., and Gabrilove, J. L. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood, 90: 4307-4312, 1997.
73. Achenbach, T. V., Muller, R., and Slater, E. P. Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J. Biol. Chem., 275: 32089-32097, 2000.
74. Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature (Lond.), 388: 300-304, 1997.
75. Deveraux, Q. L., and Reed, J. C. IAP family proteins-suppressors of apoptosis. Genes Dev., 13: 239-252, 1999.
76. Takayama, S., Bimston, D. N., Matsuzawa, S., Freeman, B. C., Aime-Sempe, C., Xie, Z., Morimoto, R. I., and Reed, J. C. BAG-1 modulates the chaperone activity of Hsp70/Hsc70. EMBO J., 16: 4887-4896, 1997.
77. Jaattela, M., Wissing, D., Kokholm, K., Kallunki, T., and Egeblad, M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J., 17: 6124-6134, 1998.
78. Bible, K. C., and Kaufmann, S. H. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
79. Bible, K. C., Bible, R. H., Jr., Kottke, T. J., Svingen, P. A., Xu, K., Pang, Y. P., Hajdu, E., and Kaufmann, S. H. Flavopiridol binds to duplex DNA. Cancer Res., 60: 2419-2428, 2000.
80. Marshall, N. F., and Price, D. H. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J. Biol. Chem., 270: 12335-12338, 1995.
81. Marshall, N. F., Peng, J., Xie, Z., and Price, D. H. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J. Biol. Chem., 271: 27176-27183, 1996.
82. Nguyen, V. T., Kiss, T., Michels, A. A., and Bensaude, O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature (Lond.), 414: 322-325, 2001.
83. Yang, Z., Zhu, Q., Luo, K., and Zhou, Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature (Lond.), 414: 317-322, 2001.
84. Portier, M., Moles, J. P., Mazars, G. R., Jeanteur, P., Bataille, R., Klein, B., and Theillet, C. p53 and RAS gene mutations in multiple myeloma. Oncogene, 7: 2539-2543, 1992.
85. Hyun, T., Yam, A., Pece, S., Xie, X., Zhang. J., Miki, T., Gutkind, J. S., and Li, W. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood, 96: 3560-3568, 2000.
86. Ge, N. L., and Rudikoff, S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene, 19: 4091-4095, 2000.